BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 سبتمبر 2024 07:00:46 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

03 سبتمبر 2024 10:02:32 بحسب NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

29 أغسطس 2024 10:17:26 بحسب NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

28 أغسطس 2024 09:45:07 بحسب NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

26 أغسطس 2024 09:45:03 بحسب NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

23 أغسطس 2024 10:45:41 بحسب NetDania Notify

BioCryst to Present at Upcoming Investor Conferences

22 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

09 أغسطس 2024 09:45:50 بحسب NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

07 أغسطس 2024 09:45:08 بحسب NetDania Notify

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

05 أغسطس 2024 07:00:24 بحسب Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 أغسطس 2024 07:00:47 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

29 يوليو 2024 09:56:40 بحسب NetDania Notify

BioCryst to Report Second Quarter 2024 Financial Results on August 5

22 يوليو 2024 07:00:09 بحسب Nasdaq GlobeNewswire

ORLADEYO® (berotralstat) Approved in Peru

09 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 يوليو 2024 07:00:06 بحسب Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 يونيو 2024 07:00:59 بحسب Nasdaq GlobeNewswire

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

02 يونيو 2024 04:00:13 بحسب Nasdaq GlobeNewswire

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

14 مايو 2024 07:00:53 بحسب Nasdaq GlobeNewswire

ORLADEYO® (berotralstat) Approved in Mexico

13 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

09 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire